Document Detail


Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer.
MedLine Citation:
PMID:  9644786     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
As postoperative adjuvant therapy for superficial bladder cancer, intravesical instillation therapy is commonly conducted. In this case, from the view point of prevention of intraoperative dissemination, commencement of instillation therapy at an early postoperative period is preferred. However, increased drug permeability is suspected because of damage to the bladder mucosa during operation. Therefore, this study was conducted to investigate the plasma level of epirubicin (EPI) instilled immediately after transurethral operation. EPI (20 mg/40 ml or 50 mg/100 ml) was instilled immediately after a transurethral operation, and retained in the bladder for 1 h. Blood samples were obtained before instillation, as well as 30, 60, 120 and 240 min after instillation, and EPI levels were assayed. The mean EPI concentrations (ng/ml) among the 20-mg/40 ml group (n = 5) were < 2.5 and < 2.0 at 30 and 60 min, respectively, after which they were undetectable. The 50-mg/100 ml group (n = 5) recorded 5.0, 4.4 and < 3.0 after 30, 60 and 120 min, respectively, and after 240 min it was undetectable. Intravesical instillation of EPI immediately after a transurethral operation causes a small increase in the plasma level and it is thought to cause small systemic side effects.
Authors:
T Tsushima; Y Miyaji; M Noda; Y Nasu; H Kumon; H Ohmori
Related Documents :
11851766 - Prognosis of conservative therapy of advanced interstitial cystitis: experience of five...
15865516 - Endoscopic cross-trigonal ureteral reimplantation under carbon dioxide bladder insuffla...
15183556 - Caecocystoplasty for intractable interstitial cystitis: long-term results.
1864026 - Postoperative urinary retention associated with total hip and total knee arthroplasties.
8764456 - Ten year experience with infrainguinal revascularization for limb salvage.
11702866 - Vasoactive treatment for hearing preservation in acoustic neuroma surgery.
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Urologia internationalis     Volume:  60     ISSN:  0042-1138     ISO Abbreviation:  Urol. Int.     Publication Date:  1998  
Date Detail:
Created Date:  1998-09-08     Completed Date:  1998-09-08     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0417373     Medline TA:  Urol Int     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  161-4     Citation Subset:  IM    
Affiliation:
Department of Urology, Okayama University Medical School, Japan. tsushima@med.okayama-u.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Absorption
Administration, Intravesical
Aged
Aged, 80 and over
Antibiotics, Antineoplastic / administration & dosage,  adverse effects,  blood*
Carcinoma, Transitional Cell / drug therapy*,  pathology,  surgery
Chemotherapy, Adjuvant
Epirubicin / administration & dosage,  adverse effects,  blood*
Humans
Male
Middle Aged
Neoplasm Staging
Postoperative Period
Treatment Outcome
Urinary Bladder Neoplasms / drug therapy*,  pathology,  surgery
Urologic Surgical Procedures / methods
Chemical
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 56420-45-2/Epirubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Biphasic action of phenylephrine on the Ca(2+)-activated K+ channel of human prostatic smooth muscle...
Next Document:  Renal needle biopsy along the retrograde puncture line of the renal calyx: a new promising technique...